ClinicalTrialsFinder

Local Institution - 0322

Al Ain City, Abu Dhabi Emirate, United Arab Emirates

1 recruiting

Showing 1–1 of 1 trials

Recruiting
Phase 2Phase 3

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868